Comparative Pharmacology
Head-to-head clinical analysis: MYHIBBIN versus NOXAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYHIBBIN versus NOXAFIL.
MYHIBBIN vs NOXAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
Posaconazole oral suspension: 200 mg (5 mL) three times daily with food. Oral delayed-release tablets: 300 mg twice daily on day 1, then 300 mg once daily thereafter with food. IV: 300 mg twice daily on day 1, then 300 mg once daily.
None Documented
None Documented
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life is approximately 25-30 hours (range 20-66 hours) in healthy subjects; in patients with hepatic impairment or critical illness, half-life may be prolonged up to 40-50 hours; supports once-daily dosing in most patients.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Primarily hepatic metabolism (glucuronidation) with extensive enterohepatic recirculation; renal excretion accounts for <1% as unchanged drug; approximately 71% of a radiolabeled dose is eliminated in feces (as parent drug and metabolites) and 13% in urine (as metabolites).
Category C
Category C
Antifungal
Antifungal